Literature DB >> 41543

Hypnotic efficacy of temazepam: a long-term sleep laboratory evaluation.

M M Mitler, M A Carskadon, R L Phillips, W R Sterling, V P Zarcone, R Spiegel, C Guilleminault, W C Dement.   

Abstract

1 Temazepam was evaluated in a strictly defined insomniac patient population under sleep laboratory conditions. Two protocols were used: a short-term (26-night) and a long-term (54-night) protocol evaluated the efficacy of the drug administered at night at 15 mg (short-term study) and 30 mg (long-term study), respectively. 2 Temazepam seemed to be both safe and effective at doses of 15 and 30 mg with up to 5 weeks of ingestion. 3 Suppression of slow wave sleep was observed at the high dose, but no suppression of REM sleep, found in studies with other benzodiazepines, was noted. 4 No evidence was found for development of tolerance or rebound effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41543      PMCID: PMC1429637          DOI: 10.1111/j.1365-2125.1979.tb00459.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Effectiveness of hypnotic drugs with prolonged use: flurazepam and pentobarbital.

Authors:  A Kales; J D Kales; E O Bixler; M B Scharf
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

2.  Flurazepam effects on slow-wave sleep: stage 4 suppressed but number of delta waves constant.

Authors:  I Feinberg; G Fein; J M Walker; L J Price; T C Floyd; J D March
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

3.  Effects of placebo and flurazepam on sleep patterns in insomniac subjects.

Authors:  J Kales; A Kales; E O Bixler; E S Slye
Journal:  Clin Pharmacol Ther       Date:  1971 Jul-Aug       Impact factor: 6.875

4.  Rebound insomnia: a new clinical syndrome.

Authors:  A Kales; M B Scharf; J D Kales
Journal:  Science       Date:  1978-09-15       Impact factor: 47.728

  4 in total
  11 in total

Review 1.  Polysomnographic effects of hypnotic drugs. A review.

Authors:  L Parrino; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

2.  The use of short- and long-acting hypnotics in clinical medicine.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

3.  Pharmacokinetics of temazepam after day-time and night-time oral administration.

Authors:  F O Müller; M Van Dyk; H K Hundt; A L Joubert; H G Luus; G Groenewoud; G C Dunbar
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Brotizolam: a sleep laboratory evaluation.

Authors:  A Vela-Bueno; J C Oliveros; B Dobladez-Blanco; S Arrigain-Ijurra; C R Soldatos; A Kales
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Hypnotics: rebound insomnia and residual sequelae.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

6.  Model insomnia by methylphenidate and caffeine and use in the evaluation of temazepam.

Authors:  T Okuma; H Matsuoka; Y Matsue; K Toyomura
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 7.  Temazepam: a review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

8.  Temazepam's efficacy in patients with sleep onset insomnia.

Authors:  T Roehrs; J Lamphere; C Paxton; R Wittig; F Zorick; T Roth
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

9.  Psycho-social stress, insomnia and temazepam: a sleep laboratory evaluation in a "general practice" sample.

Authors:  M D Beary; J H Lacey; M B Crutchfield; A V Bhat
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Temazepam 7.5 mg: effects on sleep in elderly insomniacs.

Authors:  A N Vgontzas; A Kales; E O Bixler; D C Myers
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.